The National Health Service (NHS) in the UK is funding nine trusts to pilot Skin Analytics’ artificial intelligence (AI) device for detecting cancerous skin legions.
The Cambridge-based life sciences company developed the DERM, [Deep Ensemble for the Recognition of Malignancy] device to improve GPs’ diagnostic capabilities for potential skin cancers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Utilising a smartphone-compatible device, the device captures dermoscopic images of skin lesions, which are then analysed by a deep learning algorithm that algorithm continuously improves its diagnostic accuracy through repeated analytical tasks.
Manchester University NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, University Hospitals Dorset NHS Foundation Trust, and Dorset County Hospital NHS Foundation Trust are the first trusts to be granted the £2m ($2.54m) funding from the NHS England Cancer Programme to roll out DERM, which is already being used by 12 NHS trusts and primary care providers.
According to a report on GlobalData’s Pharma Intelligence Center, the number of diagnosed incident cases of melanoma in the eight major markets (UK, US, France, Spain, Italy, Germany, Canada, and Australia) will grow by 16.61% from 190,771 cases in 2019 to 222,458 cases by 2029.
In the announcement accompanying the rollout, Skin Analytics CEO Neil Daly said: “DERM not only helps detect and assess potential cases of skin cancer but also eases pressure on routine patients seeking dermatology services. If successful, and we are confident it will be, we hope this rollout could pave the way for wider adoption across all NHS trusts in England, creating a standardised and efficient dermatology pathway.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEarlier this year, the US Food and Drug Administration (FDA) greenlit DermaSensor’s skin cancer detection device, following a pivotal study led by the Mayo Clinic, which enrolled over 1,000 patients across 22 study centres – demonstrating a 96% sensitivity rate for the device across 224 identified skin cancers.
